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Abstract
Tyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular
events (VEs). We examined the event rates and mortality among elderly patients with and without CML using
linked cancer registry and Medicare claims data from 2003 to 2010. The patients with CML had greater mor-
tality and VE rates. The rates were not elevated among the TKI (primarily imatinib)-treated patients, suggesting
the VE risk was driven by underlying factors associated with CML.
Background: Tyrosine-kinase inhibitors (TKIs) can be associated with vascular events (VEs). The expected VE rates in
patients with chronic myeloid leukemia (CML) are unknown. The present study examined the event rates and mortality
among elderly patients with and without CML. Materials and Methods: Linked Surveillance, Epidemiology, and End
Results cancer registry and Medicare claims data were used to identify patients aged  66 years with an incident (index)
diagnosis of CML from 2004 to 2009. A comparison cohort of patients without cancer was matched 1:1 to the CML
cohort. All patients were followed up from 12 months before the index diagnosis through death or December 31, 2010.
The overall survival and rates of myocardial infarction (MI), stroke, pulmonary embolism (PE), and peripheral arterial
disease (PAD) were analyzed. Results: A total of 1466 patients with CML (mean age, 78 years; average follow-up period,
25 months) were identiﬁed and matched 1:1 to a noncancer cohort (mean age, 78 years; follow-up period, 42 months).
Compared with the noncancer patients, those with CML had greater mortality (63% vs. 23% died during the follow-up
period; median survival, 23 vs. > 84 months) and greater rates of MI (33.0 vs. 11.9 per 1000 person-years), stroke (83.2
vs. 43.0), PE (6.6 vs. 2.6), and PAD (92.1 vs. 59.3; P < .01 for all). Of the 15% of CML patients with TKI claims, 97% had
received imatinib. The event rates were not elevated for TKI-treated patients compared with the overall group of patients
with CML.Conclusion: Elderly patients with CML had greater mortality and greater rates of MI, stroke, PE, and PAD than
did noncancer patients. The event rates were not elevated among the TKI-treated (primary imatinib) patients, suggesting
that the VE risk in these patients with CML was driven primarily by the underlying factors associated with CML.
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1Introduction
Chronic myeloid leukemia (CML) begins in the immature
myeloid cells of the bone marrow with formation of the BCR-ABL
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Mortality and Vascular Events Among Elderly Patients With CMLtransplantation. Tyrosine kinase inhibitors (TKIs) have been rec-
ommended as the initial treatment for most patients since 2001.1-3
The ﬁrst-generation TKI, imatinib, has been shown to result in a
substantial survival beneﬁt compared with historical CML treat-
ments. Clinical trials conducted before the availability of imatinib
reported 5-year survival rates of 65% to 70% among patients treated
with interferon-alfa therapies,4,5 and the early clinical trials of
imatinib reported 5-year overall survival of 83%.6 Second-
generation TKIs, dasatinib and nilotinib, were initially approved
in the United States as second-line treatment of CML in 2006 and
2007 and were subsequently approved as initial treatment in
October 2010 and June 2010, respectively.7,8 A newer TKI,
bosutinib (approved in September 2012), is indicated for adult
patients with CML previously treated with  1 TKIs.9 Finally, the
newest TKI, ponatinib (approved in December 2012), is indicated
for adult patients with CML or Philadelphia chromosome positive
acute lymphoblastic leukemia (Phþ ALL) with resistance or intol-
erance to dasatinib or nilotinib or with the T315I mutation.10,11
Although TKIs have improved the survival outcomes for patients
with CML, the observation of vascular events (VEs) among patients
in clinical studies of second- and newer-generation TKIs has raised
the issue of vascular safety in the CML population.12,13 In clinical
trials of nilotinib, 1.1% to 1.8% of patients experienced peripheral
arterial occlusive disease (PAOD) during a 24-month period,14 and
3.9% to 5.1% experienced ischemic heart disease during a 4-year
period.15 A retrospective study reported that 8% of patients with
CML treated with dasatinib or nilotinib experienced VEs within 28
months.16 In clinical trials of ponatinib, 8.9% of patients experi-
enced serious arterial thrombotic events (including cardiovascular,
cerebrovascular, and peripheral VEs) within 11 months,17 and 30%
experienced serious arterial occlusive event (including cardiovascu-
lar, cerebrovascular, peripheral vascular, and venous thromoembolic
events) during a 4-year period.18 A recent meta-analysis of 29
clinical studies reported an incidence rate for a composite of major
arterial events (PAOD, ischemic heart disease, stroke, or transient
ischemic attack) of 8 per 1000 patient-years for patients with CML
not treated with TKI, 11 for those treated with dasatinib, 1 for
those treated with imatinib, 4 for those treated with bosutinib, 28
for those treated with nilotinib, and 106 for those treated with
ponatinib.19
With the exception of a recent meta-analysis, very limited evi-
dence is available for the risk of VEs in patients with CML unrelated
to TKI treatment.14-16 One recent retrospective study of Swedish
patients with myeloproliferative neoplasms (MPNs) found a greater
risk of death from cardiovascular disease for patients with MPN
than for matched controls (hazard ratio [HR], 1.5-8.8, depending
on the age group).20 To the best of our knowledge, no similar
studies speciﬁcally analyzing CML have been published. Because
the VE rates have not been analyzed in a general CML population
(in contrast to non-CML patients), it is not known what proportion
of VEs will result from TKI therapy or from underlying CML
disease compared with what could be expected in a demographically
similar, non-CML population. The present study used population-
based data to examine the mortality and VE rates among elderly
patients with CML with and without evidence of TKI treatment
and compare these with the rates of patients without cancer using
US national data.Clinical Lymphoma, Myeloma & Leukemia May 2016Materials and Methods
Data Source
The present retrospective cohort study used data from the Surveil-
lance, Epidemiology, and End Results (SEER) cancer registry from
2004 through 2009, linked with the Medicare claims data from 2003
through 2010. The linked SEER-Medicare database is a collaborative
effort of the National Cancer Institute, the SEER registries, and the
Centers forMedicare andMedicaid Services. SEER is an epidemiologic
surveillance system consisting of population-based tumor registries
designed to track cancer incidence and survival in the United States.
The registries routinely collect information on patients with newly
diagnosed cancer in geographically deﬁned areas that represent
approximately 25% of the US population. The registries ascertain all
newly diagnosed cancer cases from multiple reporting sources,
including hospitals, outpatient clinics, laboratories, private clinics,
nursing homes, hospice, autopsy reports, and death certiﬁcates.
The database includes a SEERﬁle of patients diagnosedwith cancer
within the geographic areas covered by SEER registries (Patient
Entitlement and Diagnosis Summary ﬁle) and Medicare claims. The
Medicare administrative claims ﬁles include individual claims for
inpatient and skilled nursing facility hospitalizations, outpatient
hospital visits, and miscellaneous ambulatory services, home health
agency services, hospice services, carrier claims, durable medical
equipment, and part D prescription drug claims. Part D prescription
data are only available from2007 through 2010. SEER-Medicare data
have been used in numerous published studies of a variety of cancers,
including cancers of the breast,21 prostate,22 lung,23 and colon,24
among others. This source is appealing for cancer studies owing to
its size, comprehensiveness, and accessibility.
Patient Selection and Follow-Up
Two cohorts were selected for the analysis: a cohort of patients
with CML (CML cohort) and a matched comparison cohort of
patients who did not have cancer at their respective index date
(noncancer cohort). All patients in both cohorts were required to
meet the following criteria:
 Age  66 years at the index date (to allow a 1-year baseline
period before the index date)
 Entitlement for both part A and part B Medicare beneﬁts at all
points during the study period (including a 12-month baseline
period before the index date)
 Not enrolled in an health maintenance organization (HMO)
during any study month
 Medicare entitlement not based on end-stage renal disease or
disability
 No claims after the date of death
Patients with an incident diagnosis of CML (SEER site recode
78) from January 1, 2004 and December 31, 2009 were identiﬁed
for possible inclusion in the CML cohort, with the date of CML
diagnosis serving as the index date. This cohort was then limited to
those who met the following additional criteria:
 No history of any other cancer diagnosis before the CML diagnosis
 The diagnosis of CML was not at the time of death or autopsy
To create the noncancer cohort, one randomly selected patient of
identical age, gender, race, and region was matched to each CML
Kathleen Lang et alcohort patient and assigned the same index date (to follow them up
during the identical period). The noncancer patients were selected
from the Medicare enrollment ﬁles using a 5% sample of Medicare
beneﬁciaries residing in SEER areas who had not been reported to
any of the SEER registries as having any cancer before their index
date. These patients were not required to have Medicare claims to
be selected for inclusion and were included even if they developed
cancer other than CML after their index date. All patients were
followed up until the end of the study window (December 31,
2010) or death, whichever came ﬁrst. The CML cohort was strat-
iﬁed into 2 subgroups (TKI and non-TKI) according to the evi-
dence from the Medicare part D pharmacy claims for TKI therapy
during the follow-up period using the Healthcare Common Pro-
cedure Coding System or National Drug Codes or drug names (see
Appendix in the online version, for the relevant codes for imatinib,
dasatinib, and nilotinib, the only TKIs available during our study
period of 2003 to 2010; ponatinib and bosutinib were approved by
the Food and Drug Administration in 2012 and therefore were not
captured in our study period).
Study Measures
The baseline demographic and clinical characteristics were assessed
during the 12-month baseline period preceding the index date,
including age, gender, race, region, comorbidities of interest (hyper-
tension, hypercholesterolemia), and the Charlson comorbidity in-
dex.25,26 Mortality and the time from the index date to death were
evaluated for all patients. The occurrence of stroke, MI, pulmonary
embolism (PE), or peripheral arterial disease (PAD) during the
follow-up period was identiﬁed according to the presence of  2
inpatient or outpatient claims with diagnosis codes indicating the
corresponding events 1 day apart (MI, “International Classiﬁcation
of Disease, 9th revision, Clinical Modiﬁcation” [ICD-9-CM] code
410.xx; stroke, ICD-9-CM codes 433.01, 433.11, 433.21, 433.31,
433.81, 433.91, 434.00, 434.01, 434.11, 434.91, 436.xx, 430.xx-
432.xx, and 435.xx; PE, ICD-9-CM code 415.1x; PAD, ICD-9-CM
codes 250.70, 440.20-24, and 443.9x). The time to each event was
calculated as the number of months from the index date to the date of
the ﬁrst claim with the diagnosis for the relevant event. For the pa-
tients with CML with evidence of TKI treatment, the number of
months of imatinib therapy (deﬁned as the sum of days of supply for
all imatinib claims), number of months receiving a second-generation
TKI, and number of months receiving any TKI during the follow-up
period were assessed among those who had received corresponding
TKIs. Finally, the percentage of patients with CML receiving stem
cell transplantation (any claim with ICD-9-CM diagnosis code
996.88 or V42.82 or ICD-9-CM procedure code 41.04, 41.05,
41.06, 41.07, or 41.08) during follow-up was assessed.
Statistical Analysis
Descriptive analyses of all study measures were performed. Cate-
gorical variables were summarized using frequencies and percentages,
and continuous variables were summarized using the mean, standard
deviation, and median values. Statistical testing between the CML
and noncancer cohorts was conducted for mortality, overall survival,
and VE rates. Continuous variables were tested using the t test or
nonparametric Wilcoxon test, and proportions were tested using the
c2 test or Fisher’s exact test. Survival was tested using the log-ranktest. Statistical testing of VE rate was performed using the cohort
indicator as the single covariate in the Poisson regression (PROC
GENMOD procedure with the presence of event as the regression
outcome, log [number of months] as the offset). The number of
months was calculated as the interval to the ﬁrst event for those who
experienced an event and the entire follow-up time for those who did
not experience an event. All statistical tests were performed assuming
a 2-sided alpha of 0.05. All analyses were conducted using SAS
software, version 9.4 (SAS Institute, Cary, NC).
The proportion of patients in each cohort experiencing MI,
stroke, or PE during the follow-up period and the time to these
events among those who experienced such events were analyzed. In
addition, the rates of MI, stroke, and PE were reported as the
number of events per 1000 person-years (PYs). A Kaplan-Meier
survival analysis was conducted for overall survival and the time
to MI, stroke, or PE. Cox proportional hazard models were esti-
mated for overall survival, the time to MI, and the time to stroke,
controlling for age, gender, region, race, Charlson score, and base-
line comorbidities. Cox modelling was not conducted for the time
to PE because of the small number of patients with PE events. For
the CML cohort, all study measures were reported overall, as well as
stratiﬁed by the evidence of TKI use.
Results
Patient Selection
A total of 4030 patients with CML were identiﬁed in the SEER
database during 2004 to 2009. Of these, 1501 met all eligibility
criteria, and 1466 were successfully matched to noncancer patients
(the 35 patients with CML but with no matches were excluded
from the study). Figure 1 illustrates the patient selection process. Of
the 1466 patients with CML, 219 (15%) were observed to have a
Medicare part D claim or outpatient claim for TKI therapy, with
97% of these receiving imatinib therapy. Of the 219 patients with
TKI evidence, 32 received a second-generation TKI at any time
after the index date (22 dasatinib, <11 nilotinib, and <11 both
dasatinib and nilotinib). Of the TKI patients, the average number of
months of receiving imatinib for those patients was 22 months and
was 10 months for second-generation TKI and 23 months for any
TKI. The percentage with stem cell transplantation was very low
among the patients with CML receiving TKI therapy (<11 of 219)
and not receiving TKI therapy (<11 of 1247).
Demographics and Baseline Characteristics
The demographic and baseline clinical characteristics in the CML
and matched noncancer cohorts were very similar overall. The mean
age in both cohorts was 78 years, with 50% of patients aged  76
years (Table 1). More than one half (56%) were male, and most
(89%) were white in both cohorts. More than two ﬁfths of the
patients (45%) were from the West, followed by the South (21%),
Northeast (18%), and Midwest (16%). The CML cohort had
slightly greater baseline Charlson scores (excluding any primary
malignancy and metastatic solid tumor) than the noncancer cohort
(mean  standard deviation 1.6  1.8 vs. 1.0  1.6). Diabetes,
congestive heart failure, and cerebrovascular disease were common
comorbidities in both cohorts.
Within the CML cohort, the demographic and baseline clinical
characteristics were similar across the patients with evidence ofClinical Lymphoma, Myeloma & Leukemia May 2016 - 277
Figure 1 Patient Selection
Patients with newly diagnosed CML during 1/1/
2004 and 12/31/2009
(based on SEER cancer site re-code variable 78:
chronic myeloid leukemia)
N=4,030
Aged 66 years or older
N=2,855
No diagnosis of CML or other cancer of interest
made by death certificate or autopsy
N=2,482
Medicare eligibility NOT based on end-stage
renal disease or disability
N=2,461
Eligible for Medicare Part A and B in all study
months
N=2,287
Not enrolled in a health maintenance
organization (HMO) anytime during study period
N=1,639
No history of other cancer before CML
N=1,501
Post-matching criteria (1:1 based on age, sex,
race, region)
N=1,466
Abbreviations: CML ¼ chronic myeloid leukemia; SEER ¼ Surveillance, Epidemiology, and End
Results.
Mortality and Vascular Events Among Elderly Patients With CML
278 -TKI therapy and those without evidence of TKI therapy, with
the exception of age (74.8 years for TKI vs. 78.8 years for non-TKI;
P < .001), region (29.7% from the South vs. 19.2%; P ¼ .004),
congestive heart failure (16.0% vs. 23.5%; P ¼ .01), and hyper-
cholesterolemia (32.9% vs. 25.5%; P ¼ .023).Clinical Lymphoma, Myeloma & Leukemia May 2016Mortality and Survival
Almost 3 times as many patients with CML died during the
study period compared with noncancer patients (63% vs. 23%;
P < .01; Table 2), with average follow-up period correspondingly
shorter for those with CML (25 vs. 42 months). The mean time
to death among those who died was 15 months for the CML
group and 26 months for the noncancer group (P < .01). Kaplan-
Meier survival analysis indicated a median survival for CML pa-
tients of 23 months and for noncancer patients of > 84 months
(longer than the follow-up window; Figure 2). The 5-year survival
was 29% for the CML cohort compared with 72% for the non-
cancer cohort (P < .01). The patients with CML and evidence of
TKI treatment had survival outcomes similar to those in the
noncancer cohort.
Event Rates
During the follow-up period, 6.6% of those with CML
experienced a MI event, at a rate of 33.0 per 1000 PYs (Table 3,
Figure 3). In contrast, 4.0% of noncancer patients experienced a
MI event, at a rate of 11.9 per 1000 PYs (P < .01). Of those who
experienced an MI event, the time to the ﬁrst MI was shorter for
the CML cohort than for the noncancer cohort (mean, 14 vs. 26
months; median, 9 vs. 22 months; P < .01). Similarly, the pa-
tients with CML had greater rates of stroke (83.2 vs. 43.0 per
1000 PYs; P < .01), PE rates (6.6 vs. 2.6 per 1000 PYs; P <
.01), and PAD rates (92.1 vs. 59.3 per 1000 PYs; P < .001)
compared with the noncancer patients. Of those who experi-
enced a stroke, the CML patients had a shorter time to the ﬁrst
stroke (14 vs. 18 months; P ¼ .01) than that of the noncancer
patients. Of those who experienced PE, the time to the ﬁrst PE
was similar between the CML and noncancer groups (15 vs. 20
months; P ¼ .22). The percentage of patients with PAD was
similar between the CML and noncancer cohorts (16.4% vs.
17.9%; P ¼ .28).
Within the CML cohort, those with evidence of TKI therapy had
similar or lower rates of MI (31 vs. 34 per 1000 PYs; P ¼ .67),
stroke (59 vs. 91 per 1000 PYs; P ¼ .01), PE (4 vs. 8 per 1000 PYs;
P ¼ .30), and PAD (90 vs. 93; P ¼ .82) compared with patients
without evidence of TKI therapy.
Multivariable Analysis Results
After adjusting for other factors, the patients with CML
had a greater risk of death (HR, 4.2; P < .001), MI (HR, 2.5; P <
.001), and stroke (HR, 1.5; P < .001) during the follow-up period
compared with the noncancer patients (Table 4). Older age and
higher Charlson scores were signiﬁcant predictive factors for mor-
tality, MI, and stroke. African-American patients had a signiﬁcantly
greater risk of stroke compared with white patients (HR, 2.0;
P < .001). Among the CML patients only, the receipt of TKI was
not a signiﬁcant predictive factor for MI (HR, 1.2; P ¼ .52) or
stroke (HR, 0.8; P ¼ .22) during the follow-up period, after
adjustment for other factors (Table 5).
Discussion
Summary of Findings
The present study compared a cohort of patients diagnosed with
incident CML with a cohort without cancer, matched by age,
Table 1 Demographic and Baseline Clinical Characteristics Among Patients With CML and Matched Noncancer Patients
Characteristic
Noncancer Group
(n [ 1466)
CML Group
(n [ 1466)
CML With TKI
(n [ 219)
CML Without TKI
(n [ 1247)
Age (years)
Mean  SD 78.2  7.3 78.2  7.3 74.8a  6.4 78.8a  7.2
Median 78.0 78.0 74.0 79.0
Race
White 1299 (88.6) 1299 (88.6) 185a (84.5) 1114a (89.3)
African American 89 (6.1) 89 (6.1) 15a (6.8) 74a (5.9)
Otherb 78 (5.3) 78 (5.3) 19a (8.7) 59a (4.7)
Gender
Male 818 (55.8) 818 (55.8) 109 (49.8) 709 (56.9)
Female 648 (44.2) 648 (44.2) 110 (50.2) 538 (43.1)
Region
Northeast 269 (18.3) 269 (18.3) 36a (16.4) 233a (18.7)
Midwest 235 (16.0) 235 (16.0) 27a (12.3) 208a (16.7)
South 304 (20.7) 304 (20.7) 65a (29.7) 239a (19.2)
West 658 (44.9) 658 (44.9) 91a (41.6) 567a (45.5)
Year of diagnosis
2004 257 (17.5) 257 (17.5) 34 (15.5) 223 (17.9)
2005 244 (16.6) 244 (16.6) 32 (14.6) 212 (17.0)
2006 234 (16.0) 234 (16.0) 29 (13.2) 205 (16.4)
2007 227 (15.5) 227 (15.5) 31 (14.2) 196 (15.7)
2008 261 (17.8) 261 (17.8) 50 (22.8) 211 (16.9)
2009 243 (16.6) 243 (16.6) 43 (19.6) 200 (16.0)
Charlson comorbidities
Cerebrovascular disease 225c (15.3) 288c (19.6) 43 (19.6) 245 (19.6)
Congestive heart failure 195c (13.3) 328c (22.4) 35a (16.0) 293a (23.5)
Myocardial infarction 73 (5.0) 93 (6.3) 11 (5.0) 82 (6.6)
Peptic ulcer disease 34c (2.3) 69c (4.7) <11e 62 (5.0)
Peripheral vascular disease 127c (8.7) 198c (13.5) 26 (11.9) 172 (13.8)
Renal disease 82c (5.6) 158c (10.8) 16 (7.3) 142 (11.4)
Rheumatologic disease 56c (3.8) 91c (6.2) 13 (5.9) 78 (6.3)
Diabetes 365c (24.9) 460c (31.4) 76 (34.7) 384 (30.8)
Diabetes with chronic complications 81 (5.5) 126 (8.6) 24 (11.0) 102 (8.2)
Otherd 97 (6.7) 118 (8.0) 18 (8.3) 100 (8.0)
Charlson score, overall
Mean  SD 1.0c  1.6 1.6c  1.8 1.5  1.8 1.6  1.8
Median 0.0 1.0 1.0 1.0
Selected comorbidities
Hypertension 177 (12.1) 203 (13.9) 29 (13.2) 174 (14.0)
Hypercholesterolemia 346 (23.6) 390 (26.6) 72a (32.9) 318a (25.5)
Data presented as n (%), unless otherwise noted.
Abbreviations: CML ¼ chronic myeloid leukemia; SD ¼ standard deviation; TKI ¼ tyrosine kinase inhibitor.
aSigniﬁcant at P < .05, comparing CML with TKI and CML without TKI.
bIncluded Asian, Hispanic, and North American Native.
cSigniﬁcant at P < .05, comparing CML and noncancer groups.
dIncluded acquired immunodeﬁciency syndrome, chronic pulmonary disease, dementia, hemiplegia/paraplegia, and liver disease.
eNumber of patients was not reported when n < 11, in accordance with the data use agreement with SEER-Medicare to protect patient identities.
Data from Surveillance, Epidemiology, and End Results-Medicare data from 2003 to 2010.
Kathleen Lang et algender, race, and region. The mortality in the CML cohort was
almost triple that in the noncancer cohort (62.7% vs. 23.1%).
During the follow-up period, the patients with CML had greater
rates of MI, stroke, PE, and PAD compared with the rates in thenoncancer patients. The event rates were not elevated among the
TKI-treated (primary imatinib) patients, suggesting that the risk of
VEs in the patients with CML was driven primarily by underlying
risk factors associated with CML. This is consistent with evidenceClinical Lymphoma, Myeloma & Leukemia May 2016 - 279
Table 2 Survival Among Patients With CML and Matched Noncancer Patients
Characteristic
Noncancer Group
(n [ 1466)
CML Group
(n [ 1466)
CML With TKI
(n [ 219)
CML Without TKI
(n [ 1247)
Follow-up duration (mo)
Mean  SD 41.5a  22.1 25.0a  21.8 42.0b  21.5 22.0b  20.5
Median 38.0 20.0 37.0 17.0
Patients who died anytime during follow-up 338a (23.1) 919a (62.7) 40b (18.3) 879b (70.5)
Patients who died per 1000 PYs at risk after index date 67.2a 300.0a 51.6b 384.0b
Time from index to death for those who died anytime
during follow-up (mo)
Mean  SD 26.2a  19.0 15.1a  15.5 34.6b  21.2 14.2b  14.6
Median 23.0 10.0 34.5 9.0
Data presented as N (%), unless otherwise noted.
Abbreviations: CML ¼ chronic myeloid leukemia; PYs ¼ person-years; SD ¼ standard deviation; TKI ¼ tyrosine kinase inhibitor.
aSigniﬁcant at P < .05, comparing CML and noncancer groups.
bSigniﬁcant at P < .05, comparing CML with TKI and CML without TKI.
Data from Surveillance, Epidemiology, and End Results-Medicare database from 2003 to 2010.
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280 -suggesting that CML leads to alterations in platelet function owing
to the BCR-ABL mutation, and CML patients have frequent
hemorrhage or thrombosis in their medical history.27,28 To rule out
potential confounding, we divided the noncancer cohort into 2
subgroups (1 matched to TKI-treated patients and 1 matched to
non-TKI patients) and repeated our comparison of the patient
characteristics and events rates in the TKI and non-TKI groups with
the matched noncancer subgroups. The results were consistent with
the overall CML versus noncancer comparison.
Comparison With Published Data
A comparison of the 5-year survival in our noncancer population
(72%; mean age, 78 years) with the US Census estimates (75% for
age 78 years) suggested that it was generally representative of the US
population.29 The estimated event rates among the noncancer pa-
tients in our study similarly were consistent with the rates reported
in other elderly populations—an MI rate of 11.9 versus 4.5 to 22.8Figure 2 Kaplan-Meier Survival Curve for Patients With
Chronic Myeloid Leukemia (CML) and Matched
Noncancer Patients
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PYs in our study were in line with the published estimates from the
National Institutes of Health and the American Heart Associa-
tion.30,31 The observed survival for the CML cohort in our study
was also consistent with that reported by other studies. Brunner
et al32 reported a 5-year survival for CML patients aged 75 to 84 of
28% in 2004 and 36% in 2005, using SEER data. In our study, the
5-year survival for CML patients was estimated to be 29% using
Kaplan-Meier survival analysis (the mean age of our CML patients
was 78 years). An older study using SEER-Medicare data from 1991
to 1998 (which predated the use of TKI therapy) reported much
lower 5-year survival for CML patients of 13%.33 We found that
older age and African-American descent were signiﬁcant risk factors
for stroke in our study, consistent with ﬁndings from the American
Stroke Association.34
Several studies have reported cardiovascular disease rates among
patients with CML receiving TKI treatment; however, most of
them evaluated broad categories of cardiovascular conditions (eg,
PAOD, ischemic heart disease).14,15,19 Therefore, the results were
not comparable with those from our study, which observed speciﬁc
cardiovascular events.12,17 Gora-Tybor et al16 retrospectively
analyzed the rates of selected events in 105 patients with CML
treated with dasatinib or nilotinib as second-line therapy in Polish
tertiary care centers. They reported that 2% of dasatinib-treated
patients experienced MI over 29 months and 4% of nilotinib-
treated patients experienced MI over 18 months. These rates are
lower than the estimates from our study (6.6% experienced MI
during an average follow-up period of 25 months). Similarly, the
event rates in our study (MI rate, 33.9 per 1000 PYs for non-TKI
patients) were higher than those reported in a recent meta-analysis
(composite of major arterial events, 8 per 1000 PYs for the non-
TKI patients).19 Our greater estimated rates might have resulted
from our focus on an older Medicare-eligible population instead of
patients of all ages.
The results from our study suggest that VE rates are similar
among CML patients with evidence of TKI and those with no
evidence of TKI therapy. This is consistent with ﬁndings from
previous studies of imatinib (which was received by 97% of TKI
Table 3 Rates of MI, Stroke, PE, and PAD for Patients With CML and Matched Noncancer Patients
Characteristic
Noncancer Group
(n [ 1466)
CML Group
(n [ 1466)
CML With TKI
(n [ 219)
CML Without TKI
(n [ 1247)
Myocardial infarction
MI rate (per 1000 PYs) 11.9a 33.0a 30.5 33.9
MI during follow-up period 59a (4.0) 97a (6.6) 22b (10.0) 75b (6.0)
Time to ﬁrst MI from index date (mo) 26.3a  20.3 14.4a  15.7 26.6b  19.9 10.8b  12.2
Stroke
Any stroke rate (per 1000 PYs) 43.0a 83.2a 58.9b 91.0b
Any stroke during follow-up period 198 (13.5) 227 (15.5) 39 (17.8) 188 (15.1)
Time to ﬁrst stroke from index date (mo) 18.2a  18.6 14.1a  15.7 16.3  17.0 13.6  15.5
PE
PE rate (per 1000 PYs) 2.6a 6.6a 3.9 7.5
Patients with PE during follow-up period 13 (0.9) 20 (1.4) <11c 17 (1.4)
Time to ﬁrst PE from index date (mo) 19.8  15.9 14.9  18.0 26.7  11.4 12.8  18.4
PAD
PAD rate (per 1000 PYs) 59.3a 92.1a 89.6 92.9
PAD during follow-up period 262 (17.9) 240 (16.4) 56b (25.6) 184b (14.8)
Time to ﬁrst PAD from index date (mo) 15.2  16.6 12.7  14.7 13.1  15.9 12.6  14.4
Data presented as n (%) or mean  standard deviation.
Abbreviations: CML ¼ chronic myeloid leukemia; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; PE ¼ pulmonary embolism; PYs ¼ person-years; SD ¼ standard deviation;
TKI ¼ tyrosine kinase inhibitor.
aSigniﬁcant at P < .05, comparing CML and noncancer groups.
bSigniﬁcant at P < .05, comparing CML with TKI and CML without TKI.
cNumber of patients was not reported when n < 11, in accordance with the data use agreement with SEER-Medicare to protect patient identities.
Data from Surveillance, Epidemiology, and End Results-Medicare database from 2003 to 2010.
Figure 3 Rates of Myocardial Infarction (MI), Stroke, Pulmonary Embolism (PE), and Peripheral Arterial Disease (PAD) for Patients
With Chronic Myeloid Leukemia (CML) and Matched Noncancer Patients
Abbreviation: TKI ¼ tyrosine kinase inhibitor.
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Table 4 Multivariable Analysis of Time to Death, to Myocardial Infarction, and to Stroke for CML Patients and Matched Noncancer
Patients
Variable
Survival Myocardial Infarction Stroke
HR P Value HR P Value HR P Value
CML vs noncancer 4.18 <.001a 2.46 <.001a 1.54 <.001a
Age (vs 66-75 years)
76-85 years 2.11 <.001a 1.93 <.001a 1.49 <.001a
86 years 3.93 <.001a 2.86 <.001a 1.63 .001a
Female vs male gender 0.91 .12 0.73 .06 1.01 .94
Region (vs Northeast)
Midwest 1.06 .51 1.14 .61 1.15 .39
South 0.84 .06 0.86 .57 0.88 .44
West 1.04 .63 0.92 .72 1.12 .43
Race (vs white)
African American 0.81 .11 0.82 .56 1.97 <.001a
Other 0.62 .001a 1.06 .86 0.82 .40
Charlson score (vs 0)
1 1.27 .003a 0.99 .97 1.94 <.001a
2 1.88 <.001a 1.87 .01a 2.74 <.001a
Selected comorbidities (vs not)
Hypertension 1.06 .45 1.22 .37 1.03 .83
Hypercholesterolemia 0.97 .61 1.19 .34 0.96 .72
Diabetes 0.92 .24 1.32 .17 0.77 .03a
Abbreviations: CML ¼ chronic myeloid leukemia; HR ¼ hazard ratio.
aStatistically signiﬁcant, P < .05.
Data from Surveillance, Epidemiology, and End Results-Medicare database from 2003 to 2010.
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282 -patients in our study), in which it has been found that imatinib has
no obvious accumulation of VEs12 and might even have protective
effects against vascular events.35-37 The event rates were not
examined for patients receiving dasatinib or nilotinib owing to the
small sample size. Our study observed less evidence of TKI treat-
ment (14.9% among CML patients) than expected. The study
period included pre- and post-Medicare part D era (Medicare part
D was effective January 1, 2006; and pharmacy claim data were
available to us from the beginning of 2007); thus, only a fraction of
patients had part D prescription data available. Before Medicare part
D, about one third of beneﬁciaries had drug coverage through an
employer retiree health plan, and the remainder were split between
Medicaid and Medicare HMO. Some beneﬁciaries also had
coverage through private Medigap policies and low-income sub-
sidies.38 We ensured that patients with HMO coverage at any point
during the study period were excluded from the present study,
because claims information was unavailable for them. However, we
could not account for information on the care provided in other
healthcare settings (eg, Veterans Affairs) or coverage provided by
Medigap policies or Medicaid (dual eligible), which is unavailable in
SEER-Medicare. These factors likely affected our observed TKI
usage rates.
To explore whether patients with no evidence of TKI had truly
not received TKI treatment or whether they might have received
treatment through other payers or support from the manufacturer,
we conducted a subgroup analysis of only those patients withClinical Lymphoma, Myeloma & Leukemia May 2016continuous part D enrollment since 2007 and found a similar
percentage (16.5%) with evidence of TKI treatment. Furthermore,
the survival proﬁle of patients with no evidence of TKI treatment
was dramatically different from those with evidence of treatment
(18% of TKI-treated patients died during the follow-up period vs.
71% of non-TKI patients), suggesting that those without evidence
of TKI were unlikely to be receiving treatment through another
payer or through patient assistance programs from manufacturers.
Our study was not the ﬁrst to observe low treatment rates among
cancer patients. A study reported that 169 of 512 CML patients
(33%) received imatinib treatment after diagnosis, using data from
US veterans.39 It is possible that low TKI rates observed among
elderly patients with CML in our study resulted from these drugs
being expensive specialty drugs. A previous study reported that in
2008, about 99% of users of expensive oral anticancer drugs
(imatinib, erlotinib, and thalidomide) entered the coverage gap
immediately after they received their ﬁrst prescription and most of
their time was spent in the catastrophic phase.40 A previous study,
which evaluated the receipt of chemotherapy in patients with breast,
colon, rectum, or ovarian cancer, using SEER-Medicare data re-
ported that approximately one half were not receiving chemo-
therapy, although National Comprehensive Cancer Network
guidelines have generally recommended chemotherapy for these
patients and > 80% had a consultation with an oncologist.41 The
reasons for the low observed treatment rates are unknown and
represent an important area for further examination. Future studies
Table 5 Multivariable Analysis of Survival, Time to Myocardial Infarction, and Time to Stroke Among CML Patients in SEER-Medicare
Database
Variable
Survival MI Stroke
HR P Value HR P Value HR P Value
TKI vs non-TKI 0.17 <.001a 1.18 .52 0.80 .22
Age (vs 66-75 years)
76-85 years 1.72 <.001a 1.99 .004a 1.20 .22
86 years 2.80 <.001a 2.52 .004a 1.14 .55
Female vs male gender 1.01 .92 0.68 .08 1.16 .26
Region (vs Northeast)
Midwest 0.96 .69 1.11 .74 0.90 .63
South 0.83 .09 0.73 .36 0.74 .16
West 0.99 .93 0.96 .87 0.96 .83
Race (vs white)
African American 0.76 .08 0.74 .52 2.00 .002a
Other 0.88 .43 1.22 .61 1.19 .53
Charlson score (vs 0)
1 1.13 .19 0.92 .80 1.33 .12
2 1.49 <.001a 1.63 .11 1.62 .01a
Selected comorbidities (vs not)
Hypertension 1.14 .18 1.57 .07 1.19 .37
Hypercholesterolemia 1.00 .98 1.17 .49 0.87 .36
Diabetes 1.01 .94 1.47 .13 0.79 .17
Abbreviations: CML ¼ chronic myeloid leukemia; HR ¼ hazard ratio; MI ¼ myocardial infarction; SEER ¼ Surveillance, Epidemiology, and End Results; TKI ¼ tyrosine kinase inhibitor.
aStatistically signiﬁcant, P < .05.
Data from Surveillance, Epidemiology, and End Results-Medicare database from 2003 to 2010.
Kathleen Lang et alare recommended to examine TKI usage in elderly CML patients to
validate our study ﬁndings.
Study Limitations
The present study had several limitations. First, our study observed
low rates of TKI treatment (n¼ 219; 14.9% amongCMLpatients) in
elderly patients with CML. The sample size might not have been large
enough to draw any ﬁrm conclusions. Second, the SEER-Medicare
database is not representative of patients of all ages in the United
States and does not capture those with other forms of health insurance
(eg, managed care, private). Only patients aged > 66 years were
evaluated in our study, but the median age at CML diagnosis is 64
years according to the SEERdata.42 Therefore, our ﬁndingsmight not
be reﬂective of all patients with CML. For the same reason, the TKI
patients observed in our study might not have been representative of
all patients receiving a TKI, because patients receiving TKI therapy
through other approaches (eg, from an HMO) were excluded owing
to data limitations. Third, most TKI-treated patients in our sample
received only imatinib. Newer TKIs (eg, ponatinib and bosutinib)
were not available during our study period of 2003 to 2010, indicating
that our estimates of the event rates in the TKI-treated CML popu-
lation might not be representative of patients treated with second- or
third-generation TKIs. However, the present study has provided
useful estimates of VE risk attributable toCMLdisease rather than the
treatment. Fourth, VEs were identiﬁed from medical claims and thus
might reﬂect only those events for which patients soughtmedical care.The CML phase (accelerated, blast crisis, chronic) is not captured in
the database, limiting our ability to stratify analyses and outcomes by
phase. However, because most CML patients (75%-86%) have been
reported to be in the chronic phase, our study has captured the out-
comes reﬂective of the general CML population.43,44 Fifth, the pa-
tient’s clinical response to TKI (eg, results from bone marrow biopsy
and white blood cell counts) could not be measured in the database.
Finally, the study period covered 2004 to 2010 and thus did not
capture changes to the CML treatment patterns in recent years.
In addition, by using a noncancer comparison cohort, we might
have selected comparison patients with overall better health status
than the general population; thus, our estimates of background
comorbidity risk might have been biased downward. However,
because the noncancer cohort was allowed to develop other cancers
after the index date, we expect that this effect would have been
minimal. Recent studies have suggested that most deaths in patients
with newly diagnosed CML result from comorbidities rather than
the disease itself45; however, our results have indicated that CML
and comorbidities might not be independent. Thus, it is important
that our matched noncancer patients provided a valid estimate of
background comorbidity risk.
Finally, the present study was subject to the common limitations
of retrospective claims-based analyses, such as potential coding er-
rors and incomplete data.46 We focused on VEs serious enough to
be coded consistently (ie, MI, stroke, PE, and PAD) to minimize
the effect of potential coding errors. Despite its limitations, ourClinical Lymphoma, Myeloma & Leukemia May 2016 - 283
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284 -study has provide important estimates of VE rates among elderly
patients with CML with and without evidence of TKI therapy, with
a comparison with noncancer patients.
Conclusion
Elderly patients with CML had shorter survival and greater rates of
MI, stroke, PE, and PAD than matched noncancer patients. The
event rates were not elevated among patients with evidence of TKI
(primarily imatinib) use, suggesting that the excess risk in patients with
CML observed in the present study were driven primarily by under-
lying risk factors associated with CML. These ﬁndings are likely to be
of interest to clinicians considering TKI treatment for patients with
CML.
Clinical Practice Points
 Although TKIs have improved the survival outcomes for patients
with CML, the observation of VEs among patients in clinical
studies of second- and third-generation TKIs has raised concerns
regarding vascular safety in the CML population.
 Because VE rates have not been analyzed in an untreated CML
population or compared with non-CML patients, it is not
known what proportion of VEs result from TKI therapy or from
underlying CML disease compared with what would be expected
in a demographically similar, non-CML population.
 Compared with the noncancer patients, the patients with CML
had a greater risk of death (HR, 4.2; P < .001), MI (HR, 2.5;
P < .001), and stroke (HR, 1.5; P < .001).
 The event rates were similar among the patients with and
without evidence of TKI (primarily imatinib) treatment, sug-
gesting that the risk of VEs in these patients was driven primarily
by the underlying risk factors associated with CML.
 These ﬁndings are likely to be of interest to clinicians considering
TKI treatment for patients with CML.Acknowledgments
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Appendix 1 Healthcare Common Procedure Coding System
and National Drug Codes for Tyrosine Kinase
Inhibitor Therapy
Name NDC HCPCS
Imatinib 00078037366 S0088
00078040105
00078040134
00078040215
00078043815
54569584600
54868528900
54868528901
54868528902
54868528903
54868528904
54868542700
54868542701
54868542702
54868542703
66828003001
Dasatinib 00003052411
00003052711
00003052811
00003085222
00003085522
00003085722
54868575900
Nilotinib 00078052651
00078052687
00078059251
00078059287
Abbreviations: HCPCS ¼ Healthcare Common Procedure Coding System; NDC ¼ National Drug
Code.
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